Streptozocin

This classification denotes a nitrosourea compound and antineoplastic antibiotic with the molecular formula C8H15N3O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W494URQ81, chemically known as streptozotocin, pure but generally known as streptozocin, which bears US NIH Compound Identifier 5299. European Medicines Agency schedules Streptozocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10658MIG. The term STREPTOZOCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules streptozocin in its Anatomical Therapeutic Chemical (ATC) Classification. STREPTOZOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule streptozocin under HS 29419000 and SITC 54139. As of Q4 2014, STREPTOZOCIN remains the US FDA Preferred Term for this commodity. Streptozocin bears US NLM identifiers UMLS ID C0038432 and NCI Concept Code C845. SMILES: OC(C(O)C(O)CO)C(NC(=O)N(N=O)C)C=O.